
Rare Disease Drug Commercialization With Zevra Therapeutics' Neil McFarlane
Episode 307
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Neil McFarlane, CEO at Zevra Therapeutics, talks about transitioning to a focused rare disease company through acquisitions, and building out a commercial organization. Neil explains the importance of working with rare disease patient advocacy groups, using AI to analyze electronic health records and claims data to identify and diagnose patients with Niemann-Pick disease type C, and adapting to regulatory inconsistencies around rare disease drug approval frameworks in the U.S. and Europe. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Publisher
Business Of Biotech
Published
May 25, 2026
Duration
55 min
Format
Podcast
Category
Issues · Business
Source
RSS feed
Host
Ben Comer
Business Of Biotech
@businessofbiotech
#rarediseasedrug #zevratherapeuticsneil #management #lifesciences
